chronic spontaneous urticaria
Conditions
Interventions
LOU064 taken orally twice a day
Sponsors
Takamitsu Hirano
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Written informed consent must be obtained before any assessment is performed. - Willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules. - Subjects rolling over from CLOU064A2201 must have completed the Week 12 visit (end of treatment period) or the Week 16 visit (end of the follow-up period) and will be allocated to the treatment period or the observational period of CLOU064A2201E1 based on the UAS7 score (of the 7 days prior to the respective visit) as follows: - Subjects rolling over at Week 12 of CLOU064A2201 with a UAS7>=16 will be allocated to the Treatment period (note: subjects with UAS7=16 will be allocated to the Treatment period. - Subjects rolling over at Week 16 of CLOU064A2201 with a UAS7<16 will be allocated to the Observational period.
Exclusion criteria
Exclusion criteria: - Subjects having a clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact-urticarial - Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria vasculitis, urticarial pigmentosa, erythema multiforme, mastocytosis, hereditary urticaria, or acquired/drug-induced urticarial - Any other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results, eg atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis. - History or current diagnosis of ECG abnormalities indicating significant risk of safety for subjects participating in the study such as: - Concomitant clinically significant cardiac arrhythmias, eg sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker - History of familial long QT syndrome or known family history of Torsades de Pointes - Resting heart rate (physical exam or 12 lead ECG) =450 msec (male) or >=460 msec (female) at day 1 of the treatment period or inability to determine the QTcF interval - Use of agents known to prolong the QT interval unless it can be permanently discontinued for the duration of study - Significant bleeding risk or coagulation disorders - Known or suspected history of an ongoing, chronic or recurrent infectious disease including but not limited to opportunistic infections (eg tuberculosis, atypical mycobacterioses, listeriosis or aspergillosis), HIV, Hepatitis B/C Other protocol defined inclusion exclusion criteria may apply
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| long-term safety and tolerability of LOU064 [ Time Frame: overtime from week 1 to week 68 ] | — |
Countries
Argentina, Belgium, Canada, Czech Republic, Denmark, France, Hungary, Japan, Poland, Russia, Slovakia, Spain, Turkey, United Kingdom, United States
Contacts
Public ContactHirano Takamitsu
Novartis Pharma. K.K.
Outcome results
None listed